Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 29, 2026
TickeronGET DAILY SIGNALS
Why Is NovoCure (NVCR) Stock Down -9.67% Today?

Why Is NovoCure (NVCR) Stock Down -9.67% Today?

Key Takeaways

  • NVCR shares fell roughly 9.67% intraday following third-quarter results and updated guidance.
  • The selloff came despite an earnings beat, as investors focused on a slowdown in the Optune Pax pancreatic-cancer launch and a guided sequential revenue decline in the fourth quarter.
  • Competition from the newly introduced drug daraxonrasib has limited NovoCure's access to U.S. oncology practices, pressuring Optune Pax adoption.
  • The company nonetheless reported record revenue and raised full-year 2026 guidance, highlighting a disconnect between fundamentals and the market's near-term reaction.
  • Traders are now watching the Optune Pax trajectory, the NCCN pancreatic-cancer guideline update, and a year-end FDA decision on Optune Mya.
  • For deeper analysis, explore Price Targets, Earnings, and Forecast pages on Tickeron.
  • Discover how AI-driven strategies are navigating this move by visiting Trending AI Robots.

Opening Summary

NovoCure Limited (NVCR), an oncology company that develops and commercializes Tumor Treating Fields (TTFields) therapy for solid-tumor cancers, saw its stock slide sharply on Thursday. Shares traded down approximately 9.67% to around $12.80, compared with a prior closing price of $14.17. The decline followed the company's third-quarter earnings release, which beat analyst estimates but revealed a decelerating launch of its Optune Pax therapy for pancreatic cancer and a fourth-quarter revenue outlook implying a sequential pullback.

Earnings Beat, But a Bearish Backdrop

At first glance, NovoCure's Q3 2026 results appeared solid. The company reported revenue of $193.4 million, up 15.7% year over year and ahead of consensus estimates of roughly $182 million. Its net loss narrowed to $10.4 million, or $0.09 per share, from a loss of $37.3 million, or $0.33 per share, a year earlier, and the company posted positive adjusted EBITDA of $15.7 million. Management also raised full-year revenue guidance to a range of $736 million to $743 million, from $710 million to $725 million, and lifted adjusted EBITDA guidance to $24 million to $34 million.

Despite these headline beats, the market reaction was decisively negative. Analysts noted that roughly $4.4 million of the quarterly revenue reflected a one-time benefit from higher claims approval rates in the U.S. and Germany, meaning the underlying revenue surprise was smaller than it appeared. More importantly, the fourth-quarter revenue guide of $185 million to $192 million implies a sequential decline from the record third quarter, a signal investors interpreted as a near-term growth slowdown.

Optune Pax Headwinds and Competitive Pressure

The sharpest point of concern was the company's newest product, Optune Pax, approved to treat unresectable locally advanced pancreatic cancer. Management disclosed that the launch has slowed in the United States, citing the introduction of daraxonrasib, an oral KRAS inhibitor, as a key competitive threat. NovoCure said its ability to access oncology practices to detail Optune Pax is "significantly limited at this time." The company finished the quarter with 276 active Optune Pax patients and just $3.7 million in related net revenue, a modest figure that underscores how competitive dynamics are reshaping the pancreatic-cancer treatment landscape.

This commentary marked a notable shift in tone and was likely the primary catalyst behind the selloff. Even as the company's core Optune Gio business posted an 11% year-over-year increase in active patients, reaching a record 4,729, the market chose to emphasize the softer Optune Pax trajectory and its implications for the company's broader growth story.

Market Context and Trading Activity

The move came on elevated volume typical of an earnings-driven session, as investors repriced the stock following the pre-market release and accompanying conference call. The decline diverged from the broader performance of major indices and reflected stock-specific concerns rather than a sector-wide selloff. From a technical standpoint, the drop pushed shares below recent support near the $14 level and toward the lower end of the stock's recent trading range, reinforcing a weaker one-month trend that had already seen the stock pull back from higher levels.

What Comes Next for NVCR

Investors will be watching several near-term catalysts. The upcoming annual update to the NCCN guidelines for pancreatic cancer treatment is a key milestone that could influence Optune Pax reimbursement and adoption. Management is also awaiting a final FDA decision on its Optune Mya premarket approval application for brain metastases from non-small cell lung cancer, expected by year-end, with a potential launch in early 2027. Additionally, the Phase 3 KEYNOTE-D58 trial in newly diagnosed glioblastoma remains on track to complete enrollment by year-end. The principal risks center on continued competitive pressure on Optune Pax, the durability of the Optune Gio growth cycle, and whether the fourth-quarter revenue step-down proves temporary or signals a more sustained slowdown.

Trending AI Robots

Tickeron's Trending AI Robots page curates the strongest-performing AI trading bots under current market conditions. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only those demonstrating standout performance are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade. Explore the page to see how AI-driven strategies are positioned across the market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NVCR

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NVCR in -4.04% downward trend, declining for three consecutive days on November 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NVCR declined for three days, in 311 of 351 cases, the price declined further within the following month. The odds of a continued downward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVCR as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for NVCR turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 41 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

The 50-day moving average for NVCR moved below the 200-day moving average on November 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

The Aroon Indicator for NVCR entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +10.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in 205 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

NVCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. NVCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.574) is normal, around the industry mean (4.142). P/E Ratio (-10.215) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (40.950) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.634) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a commercial-stage oncology company

Industry MedicalNursingServices

Industry
Medical Specialties
Address
Grenville Street
Phone
+44 1534756700
Employees
1605
Web
https://www.novocure.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.